Professor Erika Lietzan spoke on March 16 at “Frontiers in Precision Medicine III: Will Personalized Medicine Improve Population Health?” – a full day symposium hosted by the University of Utah S.J. Quinney School of Law, the Huntsman Cancer Institute at the University of Utah, and the School of Medicine at the University of Utah. Professor Lietzan’s presentation focused on FDA regulation of direct-to-consumer genetic testing, focusing on the regulatory framework for testing services that FDA has developed in recent years, other commercial services that interpret genetic information for consumers, questions about the reach of the agency’s authority, and developments the future might hold. At the University of Missouri, Professor Lietzan teaches and writes about federal regulation of food, drugs, and devices, as well as intellectual property and administrative law. Before joining Mizzou in 2014, she practiced FDA law for 18 years in Washington, DC.